WO2003039449A3 - Modulation of dopaminergic neurons - Google Patents

Modulation of dopaminergic neurons Download PDF

Info

Publication number
WO2003039449A3
WO2003039449A3 PCT/GB2002/004880 GB0204880W WO03039449A3 WO 2003039449 A3 WO2003039449 A3 WO 2003039449A3 GB 0204880 W GB0204880 W GB 0204880W WO 03039449 A3 WO03039449 A3 WO 03039449A3
Authority
WO
WIPO (PCT)
Prior art keywords
agent
channel
bursting mode
leaving
disease
Prior art date
Application number
PCT/GB2002/004880
Other languages
French (fr)
Other versions
WO2003039449A2 (en
Inventor
Jakob Wolfart
Jochen Roeper
Original Assignee
Medical Res Council
Jakob Wolfart
Jochen Roeper
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB0126781.4A external-priority patent/GB0126781D0/en
Application filed by Medical Res Council, Jakob Wolfart, Jochen Roeper filed Critical Medical Res Council
Priority to EP02770126A priority Critical patent/EP1465609A2/en
Priority to JP2003541741A priority patent/JP2005518346A/en
Publication of WO2003039449A2 publication Critical patent/WO2003039449A2/en
Publication of WO2003039449A3 publication Critical patent/WO2003039449A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Pathology (AREA)
  • Rheumatology (AREA)
  • Toxicology (AREA)
  • Urology & Nephrology (AREA)
  • Psychology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

The present invention provides for the treatment of disease and more particularly Parkinson’s disease, an assay method for identifying and/or improving the effect of an agent causing a dopaminergic neuron to enter bursting mode and/or preventing it from leaving bursting mode, and an agent and a process of preparing a quantity of those one or more identified agents, a diagnostic method for determining whether or not an individual has a neurodegenerative disorder. The method of treatment comprises administering to a subject in need of same an agent, wherein said agent is capable of causing a dopaminergic neuron to enter bursting mode and/or of preventing it from leaving bursting mode. In a preferred aspect, the said agent modulates: a T-type channel and/or an SK (preferably SK3) channel and/or the coupling of a T-type channel with an SK (preferably SK3) channel.
PCT/GB2002/004880 2001-11-07 2002-10-30 Modulation of dopaminergic neurons WO2003039449A2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
EP02770126A EP1465609A2 (en) 2001-11-07 2002-10-30 Modulation of dopaminergic neurons
JP2003541741A JP2005518346A (en) 2001-11-07 2002-10-30 Regulation of dopaminergic neurons

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GBGB0126781.4A GB0126781D0 (en) 2001-11-07 2001-11-07 Modulation
GB0126781.4 2001-11-07
US10/216,128 US20030087799A1 (en) 2001-11-07 2002-08-09 Modulation
US10/216,128 2002-08-09

Publications (2)

Publication Number Publication Date
WO2003039449A2 WO2003039449A2 (en) 2003-05-15
WO2003039449A3 true WO2003039449A3 (en) 2004-04-15

Family

ID=26246750

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB2002/004880 WO2003039449A2 (en) 2001-11-07 2002-10-30 Modulation of dopaminergic neurons

Country Status (3)

Country Link
EP (1) EP1465609A2 (en)
JP (1) JP2005518346A (en)
WO (1) WO2003039449A2 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004035056A1 (en) * 2002-10-13 2004-04-29 Neurosearch A/S Use of skca channel blocking drugs for combating parkinson's disease
US20170056352A1 (en) 2015-08-25 2017-03-02 Rgenix, Inc. PHARMACEUTICALLY ACCEPTABLE SALTS OF beta-GUANIDINOPROPIONIC ACID WITH IMPROVED PROPERTIES AND USES THEREOF
WO2018160178A1 (en) 2017-03-01 2018-09-07 Rgenix, Inc. Pharmaceutically acceptable salts of b-guanidinopropionic acid with improved properties and uses thereof

Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4981867A (en) * 1989-12-08 1991-01-01 The Board Of Trustees Of The Leland Stanford Junior University Treatment of tremor using compounds that depress calcium currents in thalamic and other central nervous system neurons
EP0755923A1 (en) * 1995-01-23 1997-01-29 Suntory Limited Ameliorant or remedy for symptoms caused by ischemic diseases and compounds useful therefor
WO1999023072A1 (en) * 1997-10-31 1999-05-14 Suntory Limited Arylpiperidinopropanol and arylpiperazinopropanol derivatives and pharmaceuticals containing the same
WO1999028342A2 (en) * 1997-12-03 1999-06-10 Merck & Co., Inc. Low-voltage activated calcium channel compositions and methods
WO2000001676A1 (en) * 1998-07-02 2000-01-13 Neurosearch A/S Potassium channel blocking agents
US6083932A (en) * 1997-04-18 2000-07-04 Cv Technologies Inc. Pharmaceutical compositions derived from ginseng and methods of treatment using same
WO2001002406A1 (en) * 1999-06-29 2001-01-11 Neurosearch A/S Potassium channel blocking agents
WO2001002561A2 (en) * 1999-07-02 2001-01-11 Neuromed Technologies, Inc. Mammalian calcium channels and related probes, cell lines and methods
WO2001030844A1 (en) * 1999-10-26 2001-05-03 Ortho-Mcneil Pharmaceutical, Inc. Dna encoding human alpha1g-c t-type calcium channel

Patent Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4981867A (en) * 1989-12-08 1991-01-01 The Board Of Trustees Of The Leland Stanford Junior University Treatment of tremor using compounds that depress calcium currents in thalamic and other central nervous system neurons
EP0755923A1 (en) * 1995-01-23 1997-01-29 Suntory Limited Ameliorant or remedy for symptoms caused by ischemic diseases and compounds useful therefor
US6083932A (en) * 1997-04-18 2000-07-04 Cv Technologies Inc. Pharmaceutical compositions derived from ginseng and methods of treatment using same
WO1999023072A1 (en) * 1997-10-31 1999-05-14 Suntory Limited Arylpiperidinopropanol and arylpiperazinopropanol derivatives and pharmaceuticals containing the same
WO1999028342A2 (en) * 1997-12-03 1999-06-10 Merck & Co., Inc. Low-voltage activated calcium channel compositions and methods
WO2000001676A1 (en) * 1998-07-02 2000-01-13 Neurosearch A/S Potassium channel blocking agents
WO2001002406A1 (en) * 1999-06-29 2001-01-11 Neurosearch A/S Potassium channel blocking agents
WO2001002561A2 (en) * 1999-07-02 2001-01-11 Neuromed Technologies, Inc. Mammalian calcium channels and related probes, cell lines and methods
WO2001030844A1 (en) * 1999-10-26 2001-05-03 Ortho-Mcneil Pharmaceutical, Inc. Dna encoding human alpha1g-c t-type calcium channel

Non-Patent Citations (32)

* Cited by examiner, † Cited by third party
Title
ACTA PHYSIOLOGICA SCANDINAVICA. SWEDEN JAN 1986, vol. 126, no. 1, January 1986 (1986-01-01), pages 115 - 119, ISSN: 0001-6772 *
AMINO ACIDS. AUSTRIA 2001, vol. 20, no. 4, 2001, pages 353 - 362, ISSN: 0939-4451 *
BRAIN RESEARCH BULLETIN. UNITED STATES MAR 1992, vol. 28, no. 3, March 1992 (1992-03-01), pages 435 - 440, ISSN: 0361-9230 *
BRAIN RESEARCH. NETHERLANDS 21 MAY 1993, vol. 611, no. 2, 21 May 1993 (1993-05-21), pages 216 - 221, ISSN: 0006-8993 *
BRAIN RESEARCH. NETHERLANDS 25 NOV 1996, vol. 741, no. 1-2, 25 November 1996 (1996-11-25), pages 185 - 196, ISSN: 0006-8993 *
CLINICAL NEUROPHARMACOLOGY. UNITED STATES 1993, vol. 16 Suppl 1, 1993, pages S39 - S45, ISSN: 0362-5664 *
CLINICAL NEUROPHARMACOLOGY. UNITED STATES OCT 1995, vol. 18, no. 5, October 1995 (1995-10-01), pages 410 - 426, ISSN: 0362-5664 *
DATABASE MEDLINE [online] 1 May 2002 (2002-05-01), WOLFART JAKOB ET AL: "Selective coupling of T-type calcium channels to SK potassium channels prevents intrinsic bursting in dopaminergic midbrain neurons.", XP002209634, Database accession no. NLM11978817 *
DATABASE MEDLINE [online] 15 January 1999 (1999-01-15), BEURRIER C ET AL: "Subthalamic nucleus neurons switch from single-spike activity to burst-firing mode.", XP002209629, Database accession no. NLM9880580 *
DATABASE MEDLINE [online] 1989, DELUMEAU J C ET AL: "Clinical neuropharmacology of calcium antagonists.", XP002209625, Database accession no. NLM2693295 *
DATABASE MEDLINE [online] 1993, GROBE-EINSLER R: "Clinical aspects of nimodipine.", XP002209624, Database accession no. NLM8519001 *
DATABASE MEDLINE [online] 2001, ERHARDT S ET AL: "Pharmacological elevation of endogenous kynurenic acid levels activates nigral dopamine neurons.", XP002209630, Database accession no. NLM11452979 *
DATABASE MEDLINE [online] 21 May 1993 (1993-05-21), SEN A P ET AL: "Brain calcium channel related dihydropyridine and phenylalkylamine binding sites in Alzheimer's, Parkinson's and Huntington's diseases.", XP002209635, Database accession no. NLM8392892 *
DATABASE MEDLINE [online] 25 November 1996 (1996-11-25), KUPSCH A ET AL: "1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced neurotoxicity in non-human primates is antagonized by pretreatment with nimodipine at the nigral, but not at the striatal level.", XP002209622, Database accession no. NLM9001722 *
DATABASE MEDLINE [online] April 1997 (1997-04-01), MEREU G ET AL: "Spontaneous bursting activity of dopaminergic neurons in midbrain slices from immature rats: role of N-methyl-D-aspartate receptors.", XP002209632, Database accession no. NLM9130784 *
DATABASE MEDLINE [online] April 1999 (1999-04-01), MASON R P ET AL: "Inhibition of excessive neuronal apoptosis by the calcium antagonist amlodipine and antioxidants in cerebellar granule cells.", XP002209627, Database accession no. NLM10098848 *
DATABASE MEDLINE [online] August 1999 (1999-08-01), DI MATTEO V ET AL: "SB 242084, a selective serotonin2C receptor antagonist, increases dopaminergic transmission in the mesolimbic system.", XP002209633, Database accession no. NLM10462132 *
DATABASE MEDLINE [online] January 1986 (1986-01-01), NORDSTRÖM O ET AL: "Dopamine release is enhanced while acetylcholine release is inhibited by nimodipine (Bay e 9736).", XP002209621, Database accession no. NLM3953299 *
DATABASE MEDLINE [online] March 1992 (1992-03-01), GU X ET AL: "Subtypes of substantia nigra dopaminergic neurons revealed by apamin: autoradiographic and electrophysiological studies.", XP002209628, Database accession no. NLM1350500 *
DATABASE MEDLINE [online] May 2000 (2000-05-01), STOCKER M ET AL: "Differential distribution of three Ca(2+)-activated K(+) channel subunits, SK1, SK2, and SK3, in the adult rat central nervous system.", XP002209631, Database accession no. NLM10833304 *
DATABASE MEDLINE [online] November 1999 (1999-11-01), AMINI B ET AL: "Calcium dynamics underlying pacemaker-like and burst firing oscillations in midbrain dopaminergic neurons: a computational study.", XP002209626, Database accession no. NLM10561403 *
DATABASE MEDLINE [online] October 1995 (1995-10-01), MENA M A ET AL: "Effects of calcium antagonists on the dopamine system.", XP002209623, Database accession no. NLM8665555 *
FUNDAMENTAL & CLINICAL PHARMACOLOGY. FRANCE 1989, vol. 3 Suppl, 1989, pages 89s - 102s, ISSN: 0767-3981 *
JOURNAL OF NEUROCHEMISTRY. UNITED STATES APR 1999, vol. 72, no. 4, April 1999 (1999-04-01), pages 1448 - 1456, ISSN: 0022-3042 *
JOURNAL OF NEUROPHYSIOLOGY. UNITED STATES NOV 1999, vol. 82, no. 5, November 1999 (1999-11-01), pages 2249 - 2261, ISSN: 0022-3077 *
KRAMER M S ET AL: "Nifedipine in neuroleptic-refractory schizophrenia.", JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY. UNITED STATES JUN 1987, vol. 7, no. 3, June 1987 (1987-06-01), pages 195 - 196, XP008005290, ISSN: 0271-0749 *
MARCHAND L: "[Treatment of essential tremor]", L'UNION MEDICALE DU CANADA. CANADA NOV 1995, vol. 124, no. 3, November 1995 (1995-11-01), pages 32 - 34, XP008005291, ISSN: 0041-6959 *
MOLECULAR AND CELLULAR NEUROSCIENCES. UNITED STATES MAY 2000, vol. 15, no. 5, May 2000 (2000-05-01), pages 476 - 493, ISSN: 1044-7431 *
NEUROPHARMACOLOGY. ENGLAND AUG 1999, vol. 38, no. 8, August 1999 (1999-08-01), pages 1195 - 1205, ISSN: 0028-3908 *
NEUROSCIENCE. UNITED STATES APR 1997, vol. 77, no. 4, April 1997 (1997-04-01), pages 1029 - 1036, ISSN: 0306-4522 *
THE JOURNAL OF NEUROSCIENCE: THE OFFICIAL JOURNAL OF THE SOCIETY FOR NEUROSCIENCE. UNITED STATES 1 MAY 2002, vol. 22, no. 9, 1 May 2002 (2002-05-01), pages 3404 - 3413, ISSN: 1529-2401 *
THE JOURNAL OF NEUROSCIENCE: THE OFFICIAL JOURNAL OF THE SOCIETY FOR NEUROSCIENCE. UNITED STATES 15 JAN 1999, vol. 19, no. 2, 15 January 1999 (1999-01-15), pages 599 - 609, ISSN: 0270-6474 *

Also Published As

Publication number Publication date
WO2003039449A2 (en) 2003-05-15
JP2005518346A (en) 2005-06-23
EP1465609A2 (en) 2004-10-13

Similar Documents

Publication Publication Date Title
MXPA02011656A (en) Nrg 2 nucleic acid molecules, polypeptides, and diagnostic and therapeutic methods.
WO2004065576A3 (en) Methods and compositions for the treatment of urological disorder using differential expressed polypeptides
WO2005003316A3 (en) Rna processing protein complexes and uses thereof
DK0784703T3 (en) Laminin Chains: Diagnostic and Therapeutic Use
WO2005052002A3 (en) Single-domain antibodies and uses thereof
WO2003065006A3 (en) Methods and compositions for treating cancer
TW200833842A (en) Use of serum amyloid A gene in diagnosis and treatment of glaucoma and identification of anti-glaucoma agents
WO2006067792A3 (en) Aldolase autoantigens useful in diagnosis and treatment of alzheimer's disease
WO2004031414A3 (en) Method for diagnosing prostate cancer
EP1426768A3 (en) Methods for the identification of agents for the treatment of seizures, neurological diseases, endocrinopathies and hormonal diseases
WO2003039449A3 (en) Modulation of dopaminergic neurons
WO2003030725A3 (en) Pancreatic cancer diagnosis and therapies
WO2003000844A3 (en) Protein modification and maintenance molecules
WO2003070883A3 (en) Methods and compositions for treating aids and hiv-related disorders using 1414, 1481, 1553, 34021, 1720, 1683, 1552, 1682, 1675, 12825, 9952, 5816, 10002, 1611, 1371, 14324, 126, 270, 312, 167, 326, 18926, 6747, 1793, 1784, or 2045 molecules.
WO2004047757A3 (en) Diagnosing and treating hematopoietic cancers
WO2003016497A3 (en) Molecules for disease detection and treatment
WO2003000733A3 (en) Glycopeptides, their preparation and use in the diagnosis or therapeutic treatment of multiple sclerosis
WO2004001422A3 (en) Diagnostic and therapeutic use of ras-gtpase-activating sh3-domain-binding protein 2 (g3bp2) for neurodegenerative diseases
WO2004072242A3 (en) Screening of compounds for hematological disorder treatment
WO2001089558A3 (en) Formulations and use of activated protein c and protein c zymogen for treating hypercoagulable states
WO2002062300A3 (en) Cholesterol-lowering agents as treatment for psychological and cognitive disorders
WO2000071081A3 (en) Methods of diagnosis and treatment of meniere disease
WO2003028536A3 (en) Methods for diagnosing and treating heart disease
WO2002074322A3 (en) Human growth hormone for treating children with abnormal short stature and kits and methods for diagnosing gs protein dysfunctions
WO2004080535A3 (en) Methods and compositions for treating aids and hiv-related disorders using 9145, 1725, 311, 837, 58305, 156, 14175, 50352, 32678, 5560, 7240, 8865, 12396, 12397, 13644, 19938, 2077, 1735, 1786, 10220, 17822, 33945, 43748, 47161, 81982, or 46777

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LU MC NL PT SE SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2002335985

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2003541741

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 2002770126

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2002770126

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 2002770126

Country of ref document: EP